Serum protein N-glycome patterns reveal alterations associated with endometrial cancer and its phenotypes of differentiation

Background Aberrant N-glycosylation and its involvement in pathogenesis have been reported in endometrial cancer (EC). Nevertheless, the serum N-glycomic signature of EC remains unknown. Here, we investigated serum N-glycome patterns of EC to identify candidate biomarkers. Methods This study enrolled 34 untreated EC patients and 34 matched healthy controls (HC) from Peking Union Medical College Hospital. State-of-the-art MS-based methods were employed for N-glycans profiling. Multivariate and univariate statistical analyses were used to identify discriminative N-glycans driving classification. Receiver operating characteristic analyses were performed to evaluate classification accuracy. Results EC patients displayed distinct differences in serum N-glycome and had abnormal high-mannose and hybrid-type N-glycans, fucosylation, galactosylation, and linkage‐specific sialylation compared with HC. The glycan panel built with the four most discriminative and biologically important derived N-glycan traits could accurately identify EC (random forest model, the area under the curve [AUC]=0.993 [95%CI 0.955-1]). The performance was validated by two other models. Total hybrid-type N-glycans significantly associated with the differentiation types of EC could effectively stratify EC into well- or poorly-differentiated subgroups (AUC>0.8). Conclusion This study provides the initial evidence supporting the utility of serum N-glycomic signature as potential markers for the diagnosis and phenotyping of EC.

[1]  G. Bogani,et al.  Novel Insights into Molecular Mechanisms of Endometrial Diseases , 2023, Biomolecules.

[2]  G. Bogani,et al.  Recent Advances in Endometrial Cancer Management , 2023, Journal of clinical medicine.

[3]  G. Bogani,et al.  Role of Genomic and Molecular Biology in the Modulation of the Treatment of Endometrial Cancer: Narrative Review and Perspectives , 2023, Healthcare.

[4]  Y. Mechref,et al.  Exploring serum glycome patterns after moderate to severe traumatic brain injury: A prospective pilot study , 2022, EClinicalMedicine.

[5]  M. Pučić-Baković,et al.  Developments and perspectives in high-throughput protein glycomics: enabling the analysis of thousands of samples , 2022, Glycobiology.

[6]  Haojie Lu,et al.  Fast Discrimination of Sialylated N-Glycan Linkage Isomers with One-Step Derivatization by Microfluidic Capillary Electrophoresis-Mass Spectrometry. , 2022, Analytical chemistry.

[7]  A. Jemal,et al.  Cancer statistics, 2022 , 2022, CA: a cancer journal for clinicians.

[8]  Shuyang Zhang,et al.  Validation of diagnostic and predictive biomarkers for hereditary angioedema via plasma N‐glycomics , 2021, Clinical and translational allergy.

[9]  T. Ottenhoff,et al.  Immunoglobulin G1 Fc glycosylation as an early hallmark of severe COVID-19 , 2021, EBioMedicine.

[10]  Nichollas E. Scott,et al.  Community evaluation of glycoproteomics informatics solutions reveals high-performance search strategies for serum glycopeptide analysis , 2021, Nature Methods.

[11]  G. Nijpels,et al.  Plasma protein N-glycosylation is associated with cardiovascular disease, nephropathy, and retinopathy in type 2 diabetes , 2021, BMJ Open Diabetes Research & Care.

[12]  F. Amant,et al.  Cancer of the corpus uteri: 2021 update , 2021, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.

[13]  K. Reiding,et al.  Distinguishing Benign and Malignant Thyroid Nodules and Identifying Lymph Node Metastasis in Papillary Thyroid Cancer by Plasma N-Glycomics , 2021, Frontiers in Endocrinology.

[14]  Y. Mechref,et al.  MS-based glycomics and glycoproteomics methods enabling isomeric characterization. , 2021, Mass spectrometry reviews.

[15]  A. Jemal,et al.  Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries , 2021, CA: a cancer journal for clinicians.

[16]  G. Wagener Serum Glycomics, a Novel Biomarker That Opens Doors to a Better Understanding of Graft Failure. , 2021, Transplantation.

[17]  N. Packer,et al.  Altered N-linked glycosylation in endometrial cancer , 2020, Analytical and Bioanalytical Chemistry.

[18]  Erratum: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. , 2020, CA: a cancer journal for clinicians.

[19]  W. Di,et al.  Serum immunoglobulin G N-glycome: a potential biomarker in endometrial cancer , 2020, Annals of translational medicine.

[20]  X. Jia,et al.  A New Risk Index Combining d-Dimer, Fibrinogen, HE4, and CA199 Differentiates Suspecting Endometrial Cancer From Patients With Abnormal Vaginal Bleeding or Discharge , 2020, Technology in cancer research & treatment.

[21]  S. Faria,et al.  Imaging and Staging of Endometrial Cancer. , 2019, Seminars in ultrasound, CT, and MR.

[22]  M. Wuhrer,et al.  Serum protein N-glycosylation changes in multiple myeloma. , 2019, Biochimica et biophysica acta. General subjects.

[23]  Yehia Mechref,et al.  Advances in mass spectrometry‐based glycomics , 2018, Electrophoresis.

[24]  N. Wentzensen,et al.  Association of Endometrial Cancer Risk With Postmenopausal Bleeding in Women: A Systematic Review and Meta-analysis , 2018, JAMA internal medicine.

[25]  M. Wuhrer,et al.  Serum sialylation changes in cancer , 2018, Glycoconjugate Journal.

[26]  M. Delgado-Rodríguez,et al.  Systematic review and meta-analysis. , 2017, Medicina intensiva.

[27]  A. Prentice,et al.  Premenopausal abnormal uterine bleeding and risk of endometrial cancer , 2016, BJOG : an international journal of obstetrics and gynaecology.

[28]  Magnus Palmblad,et al.  MassyTools: A High-Throughput Targeted Data Processing Tool for Relative Quantitation and Quality Control Developed for Glycomic and Glycoproteomic MALDI-MS. , 2015, Journal of proteome research.

[29]  M. Wuhrer,et al.  Human plasma protein N-glycosylation , 2015, Glycoconjugate Journal.

[30]  S. Pinho,et al.  Glycosylation in cancer: mechanisms and clinical implications , 2015, Nature Reviews Cancer.

[31]  A. Talhouk,et al.  A clinically applicable molecular-based classification for endometrial cancers , 2015, British Journal of Cancer.

[32]  André M Deelder,et al.  High-throughput profiling of protein N-glycosylation by MALDI-TOF-MS employing linkage-specific sialic acid esterification. , 2014, Analytical chemistry.

[33]  Steven J. M. Jones,et al.  Integrated genomic characterization of endometrial carcinoma , 2013, Nature.

[34]  M. Toyoda,et al.  Glycan profiling of endometrial cancers using lectin microarray , 2012, Genes to cells : devoted to molecular & cellular mechanisms.

[35]  M. Schultz,et al.  Regulation of the metastatic cell phenotype by sialylated glycans , 2012, Cancer and Metastasis Reviews.

[36]  T. Herzog,et al.  Contemporary management of endometrial cancer , 2012, The Lancet.

[37]  Xiaoyan Zhang,et al.  Altered protein expression in serum from endometrial hyperplasia and carcinoma patients , 2011, Journal of hematology & oncology.

[38]  André M Deelder,et al.  Cotton HILIC SPE microtips for microscale purification and enrichment of glycans and glycopeptides. , 2011, Analytical chemistry.

[39]  F. Ghezzi,et al.  Prognostic significance of preoperative plasma fibrinogen in endometrial cancer. , 2010, Gynecologic oncology.

[40]  N. Taniguchi Toward Cancer Biomarker Discovery using the Glycomics Approach , 2008, Proteomics.

[41]  Alessio Ceroni,et al.  GlycoWorkbench: a tool for the computer-assisted annotation of mass spectra of glycans. , 2008, Journal of proteome research.

[42]  René Ranzinger,et al.  “Glyco‐peakfinder” – de novo composition analysis of glycoconjugates , 2007, Proteomics.

[43]  R. Ness,et al.  Inflammation and Endometrial Cancer: A Hypothesis , 2005, Cancer Epidemiology Biomarkers & Prevention.

[44]  A. Gadducci,et al.  Combined use of CA 125 and CA 15-3 in patients with endometrial carcinoma. , 1994, Gynecologic oncology.

[45]  Eka Swadiansa The hypothesis , 1990 .

[46]  J A Swets,et al.  Measuring the accuracy of diagnostic systems. , 1988, Science.

[47]  B. Pottakkat,et al.  A Prospective Pilot Study , 2023 .

[48]  S. Ossareh Mechanisms and Clinical Implications , 2021 .

[49]  Meenakshi Singh,et al.  Endometrial Carcinoma: Role of Current and Emerging Biomarkers in Resolving Persistent Clinical Dilemmas. , 2016, American journal of clinical pathology.

[50]  Matthew Burnell,et al.  Sensitivity of transvaginal ultrasound screening for endometrial cancer in postmenopausal women: a case-control study within the UKCTOCS cohort. , 2011, The Lancet. Oncology.

[51]  Patrick Neven,et al.  Endometrial cancer. , 2005, Lancet.

[52]  T. McDonnell,et al.  A potential biomarker for endometrial cancer , 2003 .